BOSTON--(BUSINESS WIRE)--SAGE Therapeutics, a central nervous system (CNS) product focused company developing new therapies to meet the growing unmet need in a range of CNS disorders, today announced the appointment of Albert J. Robichaud, Ph.D., to chief scientific officer. In this role, Dr. Robichaud will be responsible for advancing the company’s therapeutic pipeline for CNS disorders and moving its lead programs into clinical development. Additionally, SAGE Therapeutics has appointed Jean-Cosme (J.C.) Dodart, Ph.D., to the role of director of pharmacology.
